Malignant Pleural Mesothelioma: Update on Treatment Options with a Focus on Novel Therapies

Section of Interventional Pulmonology and Thoracic Oncology, Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, 833 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.
Clinics in chest medicine (Impact Factor: 2.17). 03/2013; 34(1):99-111. DOI: 10.1016/j.ccm.2012.12.005
Source: PubMed

ABSTRACT There is evidence that improved treatments of malignant pleural mesothelioma are increasing the quality and quantity of life for patients with mesothelioma. Multimodality treatment programs that combine maximal surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of patients with mesothelioma. Lung-sparing surgery may allow improvements in pulmonary function after surgery-based multimodality therapy, and potential longer overall survival than that seen with extrapleural pneumonectomy. Experimental treatments provide hope for all patients with mesothelioma, and in the future may be combined with standard therapy in multimodality protocols.

1 Follower
  • Source
    • "Malignant mesothelioma (MM) originates from the thin monolayer of mesothelial cells, lining the body cavities and surface of internal organs. It can arise in the pleural cavity, peritoneal cavity, pericardial cavity or tunica vaginalis, but pleural cavity is most frequently involved (~80%) [1]. A study based on WHO mortality database reported a death toll of 92,253 from MM within 1994-2008 in 83 countries [2] and global cases of MM are projected to be on the rise for decades to come [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant mesothelioma (MM) is a relatively rare cancer that occurs almost exclusively following respiratory exposure to asbestos in humans. Its pathogenesis is closely associated with iron overload and oxidative stress in mesothelial cells. Upon fiber exposure, mesothelial cells accumulate fibers simultaneously with iron, which either performs physical scissor function or catalyzes free radical generation, leading to oxidative DNA damage such as strand breaks and base modifications, followed by activation of intracellular signaling pathways. Chrysotile, per se without iron, causes massive hemolysis and further adsorbs hemoglobin. Exposure to indigestible foreign materials also induces chronic inflammation, involving consistent generation of free radicals and subsequent activation of NALP3 inflammasome in macrophages. All of these contribute to mesothelial carcinogenesis. Genomic alterations most frequently involve homozygous deletion of INK4A/4B, and other pathways such as Hippo and TGF-β pathways are also affected in MM. Recently, analyses of familial MM sorted out BAP1 as a novel responsible tumor suppressor gene, whose function is not fully elucidated. Five-year survival of mesothelioma is still ~8%, and this cancer is increasing worldwide. Connective tissue growth factor, a secretory protein creating a vicious cycle mediated by β-catenin, has been recognized as a hopeful target for therapy, especially in sarcomatoid subtype. Recent research outcomes related to microRNAs and cancer stem cells also offer additional novel targets for the treatment of MM. Iron reduction as chemoprevention of mesothelioma is helpful at least in animal preclinical study. Integrated approaches to fiber-induced oxidative stress would be necessary to overcome this currently fatal disease. (245 words). Copyright © 2015. Published by Elsevier Inc.
    Free Radical Biology and Medicine 05/2015; DOI:10.1016/j.freeradbiomed.2015.05.002 · 5.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pleural malignancies are ideal for novel therapeutic approaches because they are invariably fatal. Intrapleural (IP) chemotherapy has only marginal benefit in pleural malignancies, but may prove efficacious with hyperthermic chemotherapy administered in combination with maximal tumor debulking. IP immunotherapies may be most effective in those patients with early-stage pleural malignancy, and may prove superior to standard pleurodesis methods in control of effusion and prolongation of survival. Immunogene therapy may be unable to successfully treat bulky tumors on its own, but success may be achieved with combination approaches that combine debulking surgery and chemotherapy with IP genetic immunotherapy.
    Clinics in chest medicine 09/2013; 34(3):501-13. DOI:10.1016/j.ccm.2013.04.007 · 2.17 Impact Factor
  • Journal of Thoracic Disease 12/2013; 5(6):E246-7. DOI:10.3978/j.issn.2072-1439.2013.12.06 · 1.78 Impact Factor
Show more


Available from